Endo International PLC (NASDAQ:ENDP) will be releasing its earnings data before the market opens on Tuesday, August 8th. Analysts expect Endo International PLC to post earnings of $0.74 per share for the quarter. Endo International PLC has set its FY17 guidance at $3.45-3.75 EPS.

Endo International PLC (NASDAQ:ENDP) last posted its earnings results on Tuesday, May 9th. The company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.10 by $0.13. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The business’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the company earned $1.08 earnings per share. On average, analysts expect Endo International PLC to post $3.47 EPS for the current fiscal year and $3.26 EPS for the next fiscal year.

Endo International PLC (NASDAQ:ENDP) opened at 9.38 on Friday. Endo International PLC has a 52-week low of $9.36 and a 52-week high of $24.93. The company’s market capitalization is $2.09 billion. The firm has a 50-day moving average price of $11.45 and a 200 day moving average price of $11.76.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/08/06/endo-international-plc-nasdaqendp-set-to-announce-quarterly-earnings-on-tuesday.html.

Several brokerages recently weighed in on ENDP. William Blair restated a “market perform” rating on shares of Endo International PLC in a report on Wednesday, June 14th. Stifel Nicolaus cut Endo International PLC from a “buy” rating to a “hold” rating and dropped their target price for the company from $22.00 to $15.00 in a report on Friday, June 9th. Vetr upgraded Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 target price for the company in a report on Wednesday, May 17th. Canaccord Genuity set a $14.00 price target on Endo International PLC and gave the company a “hold” rating in a research report on Monday, May 22nd. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $15.00 price target on shares of Endo International PLC in a research report on Monday, May 1st. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have issued a buy rating to the company. Endo International PLC has a consensus rating of “Hold” and an average price target of $17.33.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Earnings History for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.